Earnings call transcript: 4C Strategies posts strong Q2 2026 rebound as stock falls

4C Strategies reported Q2 2026 net sales of SEK 95.4m (+26% YoY) and EBIT of SEK 13.2m (14% margin vs. -16% a year earlier), but shares still fell 3.77% to $9.45 as investors focused on liquidity risk (cash just SEK 1.2m). The quarter featured record momentum with order intake of SEK 683m and a record order book of SEK 960m (+222% YoY), supported by a new ~GBP 55m/15-year U.K. defense contract; however, the company did not provide a comparable EPS figure to reconcile earnings vs consensus. Management expects improved cash conversion in 2H and targets rolling-12-month cash-flow positivity by end-2025 (with guidance for Q3 2026 revenue of $7.44m and EPS of -$0.01), while also announcing a fully secured rights issue of ~SEK 54m to strengthen its financial position.

Analysis

The market is discounting balance-sheet fragility, not the P&L. In small-cap defense software, a profitable quarter is not enough if working capital is still negative and the business model requires front-loaded delivery costs before invoicing catches up; that creates a financing overhang that can suppress the multiple for several quarters even if bookings stay strong. The large contract and record backlog reduce demand risk, but they also raise execution risk because fixed-price, long-duration work can compress margins if procurement, staffing or delivery slip.

Near term, the stock likely trades on cash headlines and rights-issue mechanics rather than on revenue growth. If the capital raise is absorbed cleanly and Q3 shows materially better cash conversion, the name can rerate quickly because the market cap is so small relative to the order book; if not, dilution and liquidity concerns will dominate and any rally fades. Over 6-18 months, the real upside is not top-line growth but converting contract assets into cash and proving the U.S. pipeline can close on time.

Contrarian view: consensus is probably underestimating how much of the weakness is a timing issue, but overestimating how quickly that timing can fix itself. The key falsifier is a second straight quarter of weak operating cash flow or another slip in North America; that would argue the backlog is not economically monetizing fast enough. Conversely, a step-up in invoicing and a net cash rebuild after the rights issue would be the first real signal that the equity story can move from "survival" to "compounder".

Key Decisions for Investors

• Avoid initiating a fresh long in TSTS until the rights issue is complete and the company shows at least one quarter of meaningful cash conversion improvement; the current setup is a financing-trade, not a quality re-rating.
• If borrow is available and liquidity is sufficient, consider a tactical short into any post-rights-issue bounce, with the thesis that dilution and cash concerns cap upside until operating cash flow turns positive; cover on evidence of stronger Q3 invoicing.
• Set a watch item on Q3 operating cash flow and net cash balance: if cash rises materially from the current de minimis level and contract assets start to unwind, the stock could rerate sharply because the market cap is only ~$39m.
• Use a hard stop/falsifier: if North America delays persist into the next report or operating cash flow is still negative after the capital raise, abandon any recovery thesis and treat the order book as non-monetizing.
• For investors wanting defense exposure, prefer larger, better-capitalized defense software/infrastructure names over TSTS until execution risk and liquidity risk are resolved.